(Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant ... Unlike VKA warfarin, tecarfarin uses a unique metabolic pathway that is ...
For vitamin D to be used by the body, it has to be converted, or hydroxylated, first by the liver and then by a process involving the kidneys. According to the Office of Dietary Supplements ...